{"id":526985,"date":"2021-08-11T17:03:16","date_gmt":"2021-08-11T21:03:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/"},"modified":"2021-08-11T17:03:16","modified_gmt":"2021-08-11T21:03:16","slug":"helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

NEWTOWN, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT<\/u><\/a>) (TSX: HSM<\/u><\/a>) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that, effective\u00a0August 10, 2021, its independent directors approved an equity award under Helius\u2019 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.<\/p>\n

In connection with entering into employment with\u00a0Helius, the individual, who was not a previously employee or director of\u00a0Helius, received an option to purchase 2,000 shares of the Company\u2019s Class A common stock. The option award has an exercise price of\u00a0$15.39\u00a0per share, the closing price of Helius\u2019 common stock on\u00a0August 10, 2021, the date of the grant. The options have a ten-year term and vest over a period of four years, with 25% vesting on each of the first, second, third and fourth anniversary of August 2, 2021, provided the new hire\u2019s employment is continuing on each such date, and subject to acceleration or forfeiture upon the occurrence of certain events as set forth in the new hire\u2019s option agreement.<\/p>\n

\n About Helius Medical Technologies, Inc.<\/strong>\n <\/p>\n

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company\u2019s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain\u2019s ability to heal itself. The Company\u2019s first commercial product is the Portable Neuromodulation Stimulator (PoNS\u2122). For more information, visit\u00a0www.heliusmedical.com<\/u><\/a>.<\/p>\n

\n About the PoNS\u2122 Device and PoNS Treatment\u2122<\/strong>\n <\/p>\n

The Portable Neuromodulation Stimulator (PoNS\u2122)\u00a0is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (\u201cMS\u201d) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury (\u201cmmTBI\u201d) and is to be used in conjunction with physical therapy. PoNS is an investigational medical device in the European Union (\u201cEU\u201d) and Australia (\u201cAUS\u201d). It is currently under premarket review by the AUS Therapeutic Goods Administration.<\/p>\n

Investor Relations Contact:<\/p>\n

Westwicke on behalf of Helius Medical Technologies, Inc.
Jack Powell, Vice President
investorrelations@heliusmedical.com<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEWTOWN, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (TSX: HSM) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that, effective\u00a0August 10, 2021, its independent directors approved an equity award under Helius\u2019 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with entering into employment with\u00a0Helius, the individual, who was not a previously employee or director of\u00a0Helius, received an option to purchase 2,000 shares of the Company\u2019s Class A common … <\/p>\n

Continue reading “Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-526985","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHelius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEWTOWN, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (TSX: HSM) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that, effective\u00a0August 10, 2021, its independent directors approved an equity award under Helius\u2019 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with entering into employment with\u00a0Helius, the individual, who was not a previously employee or director of\u00a0Helius, received an option to purchase 2,000 shares of the Company\u2019s Class A common … Continue reading "Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-11T21:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjg2NCM0MzUyMzE4IzIwODIwMzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2021-08-11T21:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\"},\"wordCount\":462,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNjg2NCM0MzUyMzE4IzIwODIwMzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\",\"name\":\"Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNjg2NCM0MzUyMzE4IzIwODIwMzE=\",\"datePublished\":\"2021-08-11T21:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNjg2NCM0MzUyMzE4IzIwODIwMzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwNjg2NCM0MzUyMzE4IzIwODIwMzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"NEWTOWN, Pa., Aug. 11, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (TSX: HSM) (\u201cHelius\u201d or the \u201cCompany\u201d), a neurotech company focused on neurological wellness, today announced that, effective\u00a0August 10, 2021, its independent directors approved an equity award under Helius\u2019 2021 Inducement Plan, as a material inducement to an individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with entering into employment with\u00a0Helius, the individual, who was not a previously employee or director of\u00a0Helius, received an option to purchase 2,000 shares of the Company\u2019s Class A common … Continue reading \"Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-11T21:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjg2NCM0MzUyMzE4IzIwODIwMzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2021-08-11T21:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/"},"wordCount":462,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjg2NCM0MzUyMzE4IzIwODIwMzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/","name":"Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjg2NCM0MzUyMzE4IzIwODIwMzE=","datePublished":"2021-08-11T21:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjg2NCM0MzUyMzE4IzIwODIwMzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwNjg2NCM0MzUyMzE4IzIwODIwMzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/helius-medical-technologies-inc-reports-inducement-grant-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=526985"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/526985\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=526985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=526985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=526985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}